Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2017-05-30 Regulatory Filings
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
4SC AG: Resminostat enhances immune cell cancer cell interaction
Regulatory Filings Classification · 1% confidence The document is a press release dated May 30, 2017, announcing new preclinical data regarding the drug resminostat and detailing an upcoming oral presentation at a scientific congress. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about scientific progress and an upcoming presentation, which fits best under the general category of corporate news or regulatory announcements that don't fit specific financial reporting codes. Since it is a specific announcement about corporate/scientific progress that isn't covered by the other specific codes (like DIV, CAP, MANG, etc.), the most appropriate fallback is Regulatory Filings (RNS), which often captures press releases about operational or scientific updates distributed via services like DGAP/EQS.
2017-05-30 English
4SC AG announces updated and progressive development program
Share Issue/Capital Change Classification · 1% confidence The document is a news release dated May 16, 2017, announcing an 'updated and progressive development program' for 4SC AG's drug candidates. It details strategic plans, expected milestones (like filing an MAA, starting pivotal studies), and the intention to raise new equity. It also announces a conference call to discuss these plans and mentions that a presentation document will be available on the website. This structure—announcing strategic updates, future plans, and an associated call/presentation—is characteristic of an Investor Presentation (IP) or a general corporate update. Since it outlines strategy and future financial needs (raising equity) in detail, it functions as an investor communication. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR, IR). The mention of an accompanying presentation document suggests it is closely related to an Investor Presentation (IP). Given the content focuses heavily on strategic direction and pipeline advancement aimed at investors, 'Investor Presentation' (IP) is the most fitting category, although it is presented as a news release announcing the strategy.
2017-05-16 English
4SC AG announces updated and progressive development program
Share Issue/Capital Change Classification · 1% confidence The document is an 'Ad-hoc' announcement dated May 16, 2017, disclosing an 'inside information' according to Article 17 MAR. The core content details an 'updated and progressive development program' for drug candidates and explicitly states an 'intention to raise new capital to fund the further development'. It also mentions that a final decision on the capital raise will be announced via an 'additional ad hoc announcement'. Furthermore, it announces a public conference call to discuss the plan and includes extensive disclaimers regarding securities offerings in various jurisdictions (US, EEA, UK). This document is not a full Annual Report (10-K), an Interim Report (IR), or a specific financial release like an Earnings Release (ER). It is a strategic update that directly involves future financing activities ('intention to raise new capital'). This aligns best with the 'Capital/Financing Update' category (CAP). Although it announces a conference call, the primary purpose is the strategic and financing update, not just the announcement of the call itself (which would be RPA/RNS). The mention of capital raising is the dominant theme.
2017-05-16 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2016 bis zum 31.12.2016
Annual Report Classification · 1% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) and 'Zusammengefasster Lagebericht' (Combined Management Report) for 4SC AG for the fiscal year 2016. It contains detailed financial information, business strategy, and operational analysis. As it covers the full fiscal year and provides comprehensive financial reporting, it is classified as an Annual Report (10-K). FY 2016
2017-05-05 German
4SC AG: Progress update on pivotal RESMAIN study of resminostat in CTCL at 13th Congress of the EADO
Regulatory Filings Classification · 1% confidence The document is a press release dated May 3, 2017, from 4SC AG, titled "4SC AG: Progress update on pivotal RESMAIN study of resminostat in CTCL at 13th Congress of the EADO". It details the progress of a clinical study, mentions upcoming top-line results (early 2019), and provides background on the drug and the disease. This type of announcement, which updates investors on clinical trial progress and scientific presentations, is typically classified as an Earnings Release (ER) if it were financial results, but since it is a scientific/clinical update presented at a conference, it functions as a general corporate/investor update. Given the options, it is not a formal financial report (10-K, IR, MRQ), nor a management change (MANG), nor a dividend notice (DIV). It is a specific corporate announcement disseminated via DGAP (a service often used for regulatory news). Since it is a detailed update on company operations/pipeline progress rather than just a brief announcement that a report is available (which would be RPA/RNS), and it doesn't fit the specific financial/governance categories, it most closely aligns with a general corporate update. However, in the context of financial filings, updates on clinical trials and scientific presentations are often grouped under general news releases. Since there is no specific 'Clinical Trial Update' category, and it is not a formal Earnings Release (ER) which focuses on financial performance, the most appropriate fallback for a detailed, non-financial corporate news item that is not a formal regulatory filing (like 10-K) or a specific announcement (like DIV, MANG) is the general Regulatory Filings/News category (RNS). It is a news detail disseminated via DGAP, which explicitly mentions it distributes 'Financial/Corporate News'. I will classify this as RNS as it is a corporate news update that doesn't fit the more specific financial or governance codes.
2017-05-03 English
4SC provides Q1 2017 update
Earnings Release Classification · 1% confidence The document is titled "4SC provides Q1 2017 update" and explicitly states it "today published an interim communication as of 31 March 2017 that presents all material developments in Q1 2017". The keywords 'Quarterly / Interim Statement' and the focus on Q1 financial highlights and outlook strongly indicate a report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is an announcement of the publication, the content provided is substantial enough to be classified as the report itself, rather than just a brief 'Report Publication Announcement' (RPA), especially given the detailed financial and operational updates included. Q1 2017
2017-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.